In this study, no severe CRS was observed, and all the CRS were relieved after symptomatic support treatment, indicating that CD19-specific CAR-T cell-based therapy was relatively safe in treating secondary CNSL. This evidence concerns the gene CD19 and congenital rubella syndrome.